SCHEMBL12546752

SCHEMBL12546752

c1ccc(-c2cccc(-c3c4c(c(-c5ccccn5)c5ccccc35)-c3ccc5c6c(ccc-4c36)-c3c-5c(-c4cccc(-c5ccccc5)c4)c4cc5ccccc5cc4c3-c3ccccn3)c2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.38
HPGD P15428 5/20 0.38
MAPK1 P28482 3/20 0.38
HSD17B10 Q99714 3/20 0.38
TSHR P16473 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
GRM5 P41594 1/20 0.36
SMN1; SMN2 Q16637 7/20 0.36
KDM4E B2RXH2 5/20 0.36
NPC1 O15118 5/20 0.36
TP53 P04637 4/20 0.36
MAPT P10636 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CCR1 P32246 2/20 0.36
CCR5 P51681 2/20 0.36
CCR8 P51685 2/20 0.36
ALPL P05186 1/20 0.36
HSP90AA1 P07900 1/20 0.36
ALPI P09923 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14805255 0.85 TGFBR1 (0.40) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL12546758 0.82 CYP11B1 (0.47) HPGDMEN1SMN1; SMN2KDM4ENPC1
SCHEMBL21704897 0.81 ESR1 (0.35) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL14805249 0.81 CCR1 (0.42) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL18858084 0.80 DHODH (0.42) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL134622 0.80 DHODH (0.41) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL12546669 0.79 METAP2 (0.37) LMNAHPGDKMT2AMEN1SMN1; SMN2
SCHEMBL12546627 0.79 METAP2 (0.37) LMNAHPGDKMT2AMEN1SMN1; SMN2
SCHEMBL12032294 0.79 LMNA (0.42) LMNAHPGDMAPK1HSD17B10TSHR
SCHEMBL24662781 0.79 GRM5 (0.46) LMNAHPGDMAPK1HSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288016-B2 Fused polycyclic compound and organic light-emitting device using the compound CANON KABUSHIKI KAISHA (JP) 2012-10-16 US disclosed
US-8288016-B2 Fused polycyclic compound and organic light-emitting device using the compound CANON KABUSHIKI KAISHA (JP) 2012-10-16 US disclosed
US-20110127908-A1 FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-06-02 US disclosed
US-20110127908-A1 FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND CANON KABUSHIKI KAISHA (JP) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110127908-A1 FUSED POLYCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING THE COMPOUND RPS19, RPL19, RNF168 LMNA 2902/4885HPGD 4041/4885MAPK1 2636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.